 BOSTON, Nov. 30, 2020 GLOBE NEWSWIRE -- Aprea Therapeutics, Inc. Nasdaq: APRE, a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia AML. The Company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes MDS. 